TherapeuticsMD (TXMD) Expected to Post Earnings on Monday

TherapeuticsMD (NASDAQ:TXMD) is expected to be issuing its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect the company to post earnings of ($6.1250) per share and revenue of $19.7680 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 18, 2026 at 4:00 PM ET.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13. The firm had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $19.77 million. TherapeuticsMD had a net margin of 5.34% and a return on equity of 0.32%.

TherapeuticsMD Stock Performance

Shares of TXMD opened at $2.07 on Monday. The stock has a market cap of $23.95 million, a P/E ratio of 34.50 and a beta of 0.61. The company has a 50-day moving average of $2.04 and a two-hundred day moving average of $2.14. TherapeuticsMD has a 12-month low of $0.99 and a 12-month high of $2.95.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of TherapeuticsMD in a research report on Thursday, July 2nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC lifted its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,273 shares of the company’s stock after buying an additional 19,073 shares during the quarter. Citadel Advisors LLC owned approximately 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.